Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets—A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care
Journal of Clinical Medicine · 23.12.2025 · 15 (1) · 102
DOI: 10.3390/jcm15010102 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.12.2025. Verfasst von Graziella Ena und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Hôpital Delta, 1160 Brussels, Belgium. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sturzprophylaxe
Abstract (Originalsprache)
The next frontier in postmenopausal osteoporosis management lies not in novel pharmacological agents, but in the systematic integration of mechanism-guided drug selection, fall prevention, and long-term adherence strategies into a unified patient-centered care model. This review is intended for clinicians and clinical researchers involved in the diagnosis, treatment, and long-term management of postmenopausal osteoporosis. We provide a mechanism-to-practice framework that explicitly maps each therapeutic class to the specific molecular pathway it targets: bisphosphonates inhibit osteoclast function downstream of RANKL activation; denosumab blocks RANKL directly at the cytokine level; romosozumab inhibits sclerostin to restore Wnt-mediated bone formation. This mechanistic foundation supports a risk-stratified treatment paradigm in which antiresorptives address accelerated remodeling in moderate-risk patients, while patients at very high fracture risk—characterized by severe bone deficit or recent fragility fractures—benefit from an anabolic-first approach followed by consolidation. Beyond drug selection, we examine the persistent treatment gap in which fewer than 20% of post-fracture patients receive therapy, arguing that fall prevention—responsible for >90% of hip fractures—and medication adherence deserve equal priority in clinical practice. We further analyze key controversies, including T-score- versus FRAX-based intervention thresholds, limitations of the trabecular bone score, cost-effectiveness constraints on anabolic-first sequencing, and evidence gaps in post-denosumab transition strategies. By synthesizing mechanistic insights, guideline recommendations, and critical appraisal of current limitations, this review offers not only an overview of existing knowledge but a coherent decision-support model aimed at improving fracture prevention through comprehensive, individualized care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, Hôpital Delta, 1160 Brussels, Belgium.
- Department of Rheumatology, Hôpital Universitaire de Bruxelles (HUB), Université libre de Bruxelles (ULB), 1070 Brussels, Belgium.
ORCID-Profile: Muhammad Soyfoo
Zitieren
APA
Ena, G., & Soyfoo, M. (2025). Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets—A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care. Journal of Clinical Medicine, 15(1), 102. https://doi.org/10.3390/jcm15010102
Vancouver
Ena G, Soyfoo M. Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets—A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care. Journal of Clinical Medicine. 2025;15(1):102. doi:10.3390/jcm15010102
BibTeX
@article{Ena2025,
author = {Ena, Graziella and Soyfoo, Muhammad},
title = {Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets—A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {15},
number = {1},
pages = {102},
doi = {10.3390/jcm15010102}
}
EUVIMED